Phaseline

Targets › CSNK2A1

CSNK2A1 (Casein kinase II subunit alpha): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2030.

Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. (UniProt, P68400)

Open in Phaseline: the race on CSNK2A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Milton S. Hershey Medical CenterSilmitasertib (CX-4945)
Casein kinase II alpha inhibitor
CSNK2A1Phase 1NeuroblastomaNov 2030

Conditions

Neuroblastoma (1)

Modalities

small molecule (1)

Companies

Milton S. Hershey Medical Center (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.